Abstract Number: 2012 • ACR Convergence 2024
Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
Background/Purpose: Pegloticase, infused every 2 weeks over ≥2 hrs, lowers serum urate (SU) in patients with refractory gout. Decreasing infusion time is expected to improve…Abstract Number: 2559 • ACR Convergence 2024
Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis
Background/Purpose: The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. The aim of…Abstract Number: 0142 • ACR Convergence 2024
The Impact of Hospital Region on Mortality and Other Outcomes in Patients with Gout: A Two-Year Nationwide Analysis
Background/Purpose: Gout is characterized by chronic inflammatory arthritis caused by the deposition of monosodium urate crystals and leads to increased risk of complications, such as…Abstract Number: 0283 • ACR Convergence 2024
Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model
Background/Purpose: Patients receiving colchicine for prophylaxis of gout flares are at risk for dose-related gastrointestinal toxicity (nausea, vomiting, diarrhea, abdominal pain) if they have pre-existing…Abstract Number: 1088 • ACR Convergence 2024
Prospective Evaluation of Carotid Atherosclerosis, Urate Deposits and Inflammation After One Year of Treatment in Newly Diagnosed Gout
Background/Purpose: Carotid atherosclerosis is prevalent in patients with gout. A prior cross-sectional study at our hospital demonstrated an association between tophi and positive Power Doppler…Abstract Number: 1289 • ACR Convergence 2024
Gout Education for Primary Care Providers: A Scoping Review
Background/Purpose: Gout is the most common inflammatory arthritis. Despite widespread availability of effective therapies and management guidelines from ACR and EULAR, many gout patients remain…Abstract Number: 2013 • ACR Convergence 2024
Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities
Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…Abstract Number: 2560 • ACR Convergence 2024
Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study
Background/Purpose: Ultrasound (US) is sensitive for detecting monosodium urate (MSU) crystal depositions in gout, described as double contour (DC), tophi and aggregates. Depositions decreased during…Abstract Number: 0178 • ACR Convergence 2024
Are Participants in Gout Clinical Trials Representative of People with Gout in the General Population?
Background/Purpose: Ensuring study participants are representative of the general population is important to ensure that efficacy and safety findings of clinical trials are generalizable in…Abstract Number: 0355 • ACR Convergence 2024
Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
Background/Purpose: Patients (pts) with gout have impaired health-related quality of life (HRQoL) relating to acute or chronic inflammation from elevated serum uric acid (sUA) levels.…Abstract Number: 1089 • ACR Convergence 2024
Endothelial Activation in Gout
Background/Purpose: Gout is the most common inflammatory arthritis and is associated with increased cardiovascular (CV) disease and cardiovascular mortality. Our prior studies have suggested that…Abstract Number: 1293 • ACR Convergence 2024
Educational Quality Improvement (QI) Project to Improve Inpatient Purine Restricted Diet Order Placement for Patients Admitted with Gout Flares
Background/Purpose: Gout is a chronic, but treatable, inflammatory disease characterized by intermittent flares involving the deposition of monosodium urate crystals in and around joints. It…Abstract Number: 2014 • ACR Convergence 2024
Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial
Background/Purpose: An unhealthy diet is an important modifiable risk factor for hyperuricemia and gout and is also associated with obesity and metabolic syndrome (MetS), known…Abstract Number: 2561 • ACR Convergence 2024
Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout. A previous cross-sectional study of pre-existing gout (n=330…Abstract Number: 0206 • ACR Convergence 2024
Urate Lowering Therapy to Acute Treatment Ratio (ULTrA) Index – a Novel Quality Indicator Associated with Reduced Hospital Admissions for Gout
Background/Purpose: Gout is sub-optimally managed with under-prescribed urate lowering therapy (ULT) leading to frequent flares, increased healthcare utilization and cost.To study the burden of gout…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 45
- Next Page »